- Home
- GNLX vs CNTB Comparison
GNLX vs CNTB Comparison
Compare GNLX & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | CNTB |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 128.6M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNLX | CNTB |
|---|---|---|
| Price | $2.66 | $2.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $19.75 | $8.50 |
| AVG Volume (30 Days) | ★ 150.4K | 116.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.10 | ★ 75.22 |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $26,033,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,617.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $0.51 |
| 52 Week High | $8.54 | $3.28 |
Technical Indicators
Market Signals| Indicator | GNLX | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 56.38 |
| Support Level | $2.54 | $2.30 |
| Resistance Level | $2.80 | $2.86 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 17.20 | 67.16 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.